Cost of diabetes treatment will likely be reduced after HC order on drug patent |
News and Updates
eMediNexus Coverage from: 
Cost of diabetes treatment will likely be reduced after HC order on drug patent

2 Read Comments                

The cost for treating diabetes will likely reduce as the Delhi high court has dismissed an appeal by AstraZeneca seeking the restraining of the generic versions of a blockbuster drug.The company was also suing some domestic companies for infringement of patents covering the drug. The court order will allow for more affordable versions of the anti-diabetes drug dapagliflozin by Indian companies.A division bench of the Delhi High Court, on July 20, dismissed AstraZeneca’s appeal, and stated ...
To read the complete article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now